Arbor Biotechnologies, Inc.

New England Biolabs, Inc.

Shaorong Chong

Winston X Yan

David R Cheng

David Arthur Scott

Jennifer Ong

Vladimir Potapov

George Tzertzinis

Quinton Norman Wessells

Pratyusha Hunnewell

Haruichi Asahara

Kuo-Chan Hung

Anthony James Garrity

Brendan Jay Hilbert

Wei-Cheng Lu

Lauren E Alfonse

Ming-Qun Xu

Thomas C Evans

Noah Michael Jakimo

Tia Marie Ditommaso

Roy Ziblat

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid.

CRISPR RNA targeting enzymes and systems and uses thereof

The present disclosure relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The disclosure further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.

Compositions comprising a CRISPR nuclease and uses thereof

A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.

Thermostable variants of T7 RNA polymerase

The present invention relates to variant polypeptides, methods of preparing the variant polypeptides, processes for characterizing the variant polypeptides, compositions and cells comprising the variant polypeptides, and methods of using the variant polypeptides. The invention further relates to complexes comprising the variant polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.

Compositions comprising a variant polypeptide and uses thereof

The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.

CRISPR DNA targeting enzymes and systems

The present invention relates to variant Cas12i4 polypeptides, methods of producing the variant Cas12i4 polypeptides, processes for characterizing the variant Cas12i4 polypeptides, cells comprising the variant Cas12i4 polypeptides, and methods of using the variant Cas12i4 polypeptides. The invention further relates to complexes comprising a variant Cas12i4 polypeptide and an RNA guide, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.

Compositions comprising a variant Cas12i4 polypeptide and uses thereof

Crispr DNA targeting enzymes and systems

A method for the ligation of expressed proteins which utilizes inteins, for example the RIR1 intein from, is provided. Constructs of the Mth RIR1 intein in which either the C-terminal asparagine or N-terminal cysteine of the intein are replaced with alanine enable the facile isolation of a protein with a specified N-terminal, for example, cysteine for use in the fusion of two or more expressed proteins. The method involves the steps of generating a C-terminal thioester-tagged target protein and a second target protein having a specified N-terminal via inteins, such as the modified Mth RIR1 intein, and ligating these proteins. A similar method for producing a cyclic or polymerized protein is provided. Modified inteins engineered to cleave at their C-terminus or N-terminus, respectively, and DNA and plasmids encoding these modified inteins are also provided.

Intein-mediated protein ligation of expressed proteins

Growing community of inventors

Somerville, MA, United States of America

Shaorong Chong